Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10936752 | 0.80 | HTT (0.58) | HTTALDH1A1NCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL1541692 | 0.78 | TAAR1 (0.57) | HTTALDH1A1NCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL7039441 | 0.78 | HTT (0.51) | HTTALDH1A1NCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL13621464 | 0.78 | TAAR1 (0.57) | HTTALDH1A1NCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL13621571 | 0.78 | TAAR1 (0.57) | HTTALDH1A1NCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL18065741 | 0.78 | HTT (0.51) | HTTALDH1A1NCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL2096552 | 0.78 | HTT (0.51) | HTTALDH1A1NCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL6932504 | 0.78 | L3MBTL1 (0.57) | HTTALDH1A1NCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL6520812 | 0.78 | HTT (0.60) | HTTALDH1A1NCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL28745498 | 0.77 | CCR3 (0.64) | HTTALDH1A1NCOA1SMN1; SMN2NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012723-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-10 | — | — | US | claimed |
| US-20100274025-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-28 | — | — | US | claimed |
| US-20090018311-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | US | claimed |
| EP-2505579-B1 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | ASTRAZENECA AB (SE) | 2014-11-05 | — | — | EP | disclosed |
| EP-2792672-A2 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | AstraZeneca AB (SE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2505578-B1 | Methods and Compounds for Producing Dipeptidyl Peptidase IV Inhibitors and Intermediates thereof | ASTRAZENECA AB (SE) | 2014-09-24 | — | — | EP | disclosed |
| EP-2517706-B1 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | ASTRAZENECA AB (SE) | 2014-06-25 | — | — | EP | disclosed |
| EP-1581487-B1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | ASTRAZENECA AB (SE) | 2014-06-04 | — | — | EP | disclosed |
| US-20130012723-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-10 | — | — | US | disclosed |
| EP-2517706-A2 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | Bristol-Myers Squibb Company (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2505578-A2 | Methods and Compounds for Producing Dipeptidyl Peptidase IV Inhibitors and Intermediates thereof | Bristol-Myers Squibb Company (US) | 2012-10-03 | — | — | EP | disclosed |
| EP-2505579-A2 | Methods and compounds for producing dipeptidyl peptidase iv inhibitors and intermediates thereof | Bristol-Myers Squibb Company (US) | 2012-10-03 | — | — | EP | disclosed |
| US-8278462-B2 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100274025-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-28 | — | — | US | disclosed |
| US-7705033-B2 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090018311-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | US | disclosed |
| US-7420079-B2 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-02 | — | — | US | disclosed |
| US-20050090539-A1 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274025-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | DPP4, DPP3, DPP8 | HTT 2391/4885ALDH1A1 1007/4885NCOA1 4537/4885 |
| US-20050090539-A1 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | DPP4, DPP3, DPP8 | HTT 2391/4885ALDH1A1 1007/4885NCOA1 4537/4885 |
| US-20090018311-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | DPP4, DPP3, DPP8 | HTT 2391/4885ALDH1A1 1007/4885NCOA1 4537/4885 |
| US-20130012723-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | DPP4, DPP3, DPP8 | HTT 2391/4885ALDH1A1 1007/4885NCOA1 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.